^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Clear Cell Renal Cell Carcinoma

    Related cancers:
    1d
    MAOB promotes ROS-mediated DNA damage, triggering a cyclic MAOB-HNF1A-53BP1-p53 axis that suppresses the malignancy of clear cell renal cell carcinoma. (PubMed, Redox Biol)
    Regarding therapeutic aspects, we discovered that DNA methyltransferase inhibitors serve as potential MAOB inducer in ccRCC. The current findings reveal novel mechanisms by which MAOB suppresses the malignancy of ccRCC and suggest that MAOB may serve as a valuable prognostic marker in the management of ccRCC.
    Journal
    |
    TP53BP1 (Tumor Protein P53 Binding Protein 1) • HNF1A (HNF1 Homeobox A)
    2d
    PANoptosis-related gene clusters and prognostic risk model in clear cell renal cell carcinoma. (PubMed, Front Genet)
    Additionally, the PRG risk score model exhibited significant associations with sensitivity to multiple drugs. This novel PANoptosis-based model addresses the knowledge gap by providing enhanced prognostic accuracy and clinical utility for personalized ccRCC management, potentially guiding targeted and immunotherapeutic strategies.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • WDR72 (WD Repeat Domain 72) • ANLN (Anillin Actin Binding Protein) • SLC16A12 (Solute Carrier Family 16 Member 12)
    2d
    CT/MRI imaging and immunohistochemical analyses of eosinophilic vacuolar tumor of the kidney: case reports of four patients. (PubMed, Abdom Radiol (NY))
    EVT is a rare renal tumor entity with characteristic imaging features, though its imaging presentation may vary depending on the underlying pathology. Accurate identification of EVT will contribute to improving the classification and diagnosis of renal tumors.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • CDH1 (Cadherin 1) • CA9 (Carbonic anhydrase 9) • VIM (Vimentin) • PAX8 (Paired box 8)
    2d
    New targets of PET imaging for renal cancer. (PubMed, Semin Nucl Med)
    In conclusion, molecular imaging is increasingly recognized as a valuable tool in the diagnosis and management of RCC. Larger, multicenter studies are essential to define its role in routine clinical practice and to fully explore its potential in future theranostic applications.
    Review • Journal • IO biomarker
    |
    CD70 (CD70 Molecule) • CA9 (Carbonic anhydrase 9)
    3d
    Gypenoside LI Inhibits Renal Cancer Proliferation by Affecting Lipid Metabolism through the Upregulation of Dual-Specificity Phosphatase 1. (PubMed, Comb Chem High Throughput Screen)
    Gyp LI upregulates DUSP1 to suppress the metabolism of choline, linoleic acid, and alpha-linolenic acid, ultimately suppressing the incidence and progression of ccRCC.
    Journal
    |
    DUSP1 (Dual Specificity Phosphatase 1)
    3d
    A pan-cancer analysis to predict the prognosis and immunological role of copper death-related gene DLAT. (PubMed, Medicine (Baltimore))
    Considering the prognostic implications of DLAT in tumors and its correlations with immune indicators, it is plausible to regard DLAT as both a prognosis feature for certain malignancies and an evaluative metric for immunotherapy efficacy. The findings suggest that DLAT could be a potential therapeutic target and serve as a biomarker for predicting patient outcomes and guiding treatment strategies in various cancers, with its prognostic and immunological implications likely to be context-dependent across different tumor types.
    Journal • Tumor mutational burden • IO biomarker • Pan tumor
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • DLAT (Dihydrolipoamide S-Acetyltransferase)
    3d
    NIRADO: Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (clinicaltrials.gov)
    P2, N=51, Terminated, Gustave Roussy, Cancer Campus, Grand Paris | Trial completion date: Dec 2027 --> Feb 2025 | Suspended --> Terminated; Abandon of the partner, GSK
    Trial completion date • Trial termination • Pan tumor • Platinum sensitive
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • ARID1A (AT-rich interaction domain 1A) • PBRM1 (Polybromo 1) • CDK12 (Cyclin dependent kinase 12) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • ARID2 (AT-Rich Interaction Domain 2) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • RAD54L (DNA Repair And Recombination Protein RAD54) • DRD (DNA Repair Deficiency)
    |
    HER-2 positive • HER-2 amplification • DDR • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    3d
    Inhibition of glycolysis and stimulation of mitochondrial biogenesis lead to increased ROS levels and cell death in HNF-1ß positive clear cell carcinoma. (PubMed, Cell Death Dis)
    The GSK-3ß inhibitor and Actinonin combination demonstrated a powerful tumor-suppressive effect in vivo without severe side effects. Combining GSK-3ß inhibition with Actinonin can effectively eliminate cancer cells with HNF-1ß overexpression by inhibiting glycolysis and promoting mitochondrial turnover, highlighting new options for cancer therapy.
    Journal
    |
    GADD45A (Growth arrest and DNA-damage-inducible, alpha) • AMPK (Protein Kinase AMP-Activated Catalytic Subunit Alpha 1)
    |
    ROS1 positive
    3d
    A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Fudan University
    New P2 trial
    |
    Lenvima (lenvatinib) • Enweida (envafolimab)
    4d
    Application of three-dimensional Superb micro-vascular imaging (3D-SMI) combined with quantitative blood flow analysis in the noninvasive diagnosis of renal tumors. (PubMed, Ultrasound J)
    3D-SMI provides three-dimensional visualization of Vascular Architecture. Quantitative analysis of the most vascularized plane using Area and VI differentiation between benign and malignant renal tumors, with VI demonstrating the best diagnostic efficacy. This technique offers a non-invasive diagnostic approach for renal tumors.
    Journal
    |
    TFE3 (Transcription Factor Binding To IGHM Enhancer 3)
    4d
    COL6A2 drives clear cell renal cell carcinoma progression via integrin-dependent modulation of Wnt/β-catenin signaling. (PubMed, J Cancer)
    COL6A2 promotes ccRCC aggressiveness and modulates Wnt/β-catenin signaling in an integrin-dependent manner. These findings nominate the COL6A2-integrin interface as a potential therapeutic and biomarker axis in ccRCC.
    Journal
    |
    COL6A2 (Collagen Type VI Alpha 2 Chain)
    4d
    Transcription factor Zfx regulates tumor's evasion to T cell killing in immunotherapy. (PubMed, iScience)
    In addition, we find that higher ZFX expression in patients with melanoma correlates with a positive response to anti-PD-1 immunotherapy. Our results demonstrate a novel resistant mechanism in tumor cells, highlighting ZFX as a potential biomarker for immunotherapy response, and suggest that targeting tumor cell intrinsic resistance genes in combination with immune therapies could benefit patients with cancer.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CASP3 (Caspase 3)